BIOPTIK Business Summary

Bioptik Technology Inc. (4161.TWO) operates a diversified biomedical business model, generating revenue through the research, manufacturing, and global distribution of medical diagnostic devices, functional health supplements, and medical-grade skincare products. The company’s primary business segments include Home-use Medical Monitoring (marketed under the EasyTouch and EasyMate brands), which features multi-parameter handheld devices for tracking glucose, cholesterol, uric acid, and hemoglobin; Beauty Care (Acureal brand), focusing on biological cosmetics and wound-healing materials; and Dietary Supplements (YuJian brand), utilizing proprietary extraction technologies for ingredients like astaxanthin. As of early 2026, Bioptik is aggressively expanding its footprint into Southeast Asian and African markets with next-generation pathogen detection and multi-parameter monitoring systems. Its primary direct competitors include TaiDoc Technology Corporation (4736.TW), Bionime Corporation (4737.TW), and Apex Biotechnology Corp. (1733.TW); Bioptik distinguishes itself through a unique integration of point-of-care diagnostics with a vertically integrated functional nutrition and skincare ecosystem. Leadership is anchored by Chairman Chin-Chang Yang, a veteran innovator with specialized expertise in medical detection devices, astaxanthin extraction, and wound therapy. The executive management team is led by Co-CEOs Yi-Ling Yang and Richard Tu; Yi-Ling Yang brings a background in medical diagnostics and veterinary medicine, while Richard Tu oversees research and development for food supplements and biomedical materials. The company was founded in 1999 in the Hsinchu Science Park and has maintained a highly stable governance structure, with a board of directors boasting an average tenure of over 18 years. While primarily held by founding members and local institutional investors, the company’s strategic roadmap for 2026 emphasizes new global partnerships to leverage its EU-certified product pipeline across more than 70 countries.